Yili Yang

8.7k total citations · 4 hit papers
103 papers, 7.2k citations indexed

About

Yili Yang is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Yili Yang has authored 103 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 41 papers in Oncology and 27 papers in Immunology. Recurrent topics in Yili Yang's work include Ubiquitin and proteasome pathways (20 papers), Cancer-related Molecular Pathways (16 papers) and Immune Cell Function and Interaction (12 papers). Yili Yang is often cited by papers focused on Ubiquitin and proteasome pathways (20 papers), Cancer-related Molecular Pathways (16 papers) and Immune Cell Function and Interaction (12 papers). Yili Yang collaborates with scholars based in China, United States and Japan. Yili Yang's co-authors include Jonathan D. Ashwell, Allan M. Weissman, Jane P. Jensen, Shengyun Fang, Xiyun Yan, Kelong Fan, Xiaoming Li, YU Xiao-dan, Jirouta Kitagaki and Chou-Chi H. Li and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Yili Yang

101 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic Stimuli

2000 819 citations Yili Yang, Shengyun Fang et al. profile →
High-Performance Self-Cascade Pyrite Nanozymes for Apoptosis–Ferroptosis Synergistic Tumor Therapy

2021 390 citations Xiangqin Meng, Dandan Li et al. ACS Nano profile →
A Thrombin‐Activated Peptide‐Templated Nanozyme for Remedying Ischemic Stroke via Thrombolytic and Neuroprotective Actions

2023 158 citations Ruofei Zhang, Yili Yang et al. profile →
A natural biogenic nanozyme for scavenging superoxide radicals

2024 88 citations Long Ma, Jia‐Jia Zheng et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yili Yang China	45	4.5k	1.5k	1.3k	1.0k	984	103	7.2k
Hongjuan Cui China	42	4.9k 1.1×	1.6k 1.1×	955 0.8×	1.9k 1.8×	265 0.3×	254	7.8k
Vincent L. Cryns United States	51	5.7k 1.3×	1.5k 1.0×	629 0.5×	898 0.9×	386 0.4×	106	9.1k
Jing Gao China	37	2.8k 0.6×	838 0.6×	1.1k 0.8×	538 0.5×	381 0.4×	176	5.3k
Shailendra Giri United States	45	3.5k 0.8×	944 0.6×	1.0k 0.8×	1.0k 1.0×	350 0.4×	137	6.8k
Pinku Mukherjee United States	45	3.0k 0.7×	2.1k 1.4×	1.9k 1.5×	619 0.6×	628 0.6×	122	6.8k
Yuxin Yin China	48	6.6k 1.5×	2.8k 1.9×	881 0.7×	1.8k 1.7×	314 0.3×	202	9.3k
Wen Liu China	45	5.0k 1.1×	952 0.6×	892 0.7×	1.1k 1.1×	245 0.2×	226	7.2k
Yubin Zhou United States	45	3.5k 0.8×	617 0.4×	734 0.6×	539 0.5×	350 0.4×	178	6.1k
Claudio Arra Italy	47	3.5k 0.8×	1.6k 1.1×	817 0.6×	1.1k 1.0×	175 0.2×	162	6.5k
Li Fu China	52	5.2k 1.2×	2.1k 1.4×	1.4k 1.1×	2.4k 2.3×	199 0.2×	242	8.8k

Countries citing papers authored by Yili Yang

Since Specialization

Citations

This map shows the geographic impact of Yili Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yili Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yili Yang more than expected).

Fields of papers citing papers by Yili Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yili Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yili Yang. The network helps show where Yili Yang may publish in the future.

Co-authorship network of co-authors of Yili Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Yili Yang. A scholar is included among the top collaborators of Yili Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yili Yang. Yili Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Long, Jia‐Jia Zheng, N. Zhou, et al.. (2024). A natural biogenic nanozyme for scavenging superoxide radicals. Nature Communications. 15(1). 233–233. 88 indexed citations breakdown →

Lu, Yisheng, et al.. (2024). Serum CXCL12 and S100A12 levels in peripheral blood fluid and their correlation with severity in patients with knee osteoarthritis. Journal of Medical Biochemistry. 44(1). 11–16.

Fang, Long, Ruofei Zhang, Lin Shi, et al.. (2023). Protein‐Nanocaged Selenium Induces t(8;21) Leukemia Cell Differentiation via Epigenetic Regulation. Advanced Science. 10(35). e2300698–e2300698. 7 indexed citations

Yang, Yili, et al.. (2023). Development of Sequence‐Controlled, Degradable, and Cytocompatible Oligomers with Explicit Fragmentation Pathways. Macromolecular Rapid Communications. 44(6). 1 indexed citations

Meng, Xiangqin, Dandan Li, Lei Chen, et al.. (2021). High-Performance Self-Cascade Pyrite Nanozymes for Apoptosis–Ferroptosis Synergistic Tumor Therapy. ACS Nano. 15(3). 5735–5751. 390 indexed citations breakdown →

Zhao, Shuai, Hongxia Duan, Yili Yang, Xiyun Yan, & Kelong Fan. (2019). Fenozyme Protects the Integrity of the Blood–Brain Barrier against Experimental Cerebral Malaria. Nano Letters. 19(12). 8887–8895. 88 indexed citations

Ku, Xin, Yan Xu, Chunlin Cai, et al.. (2019). In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers. Analytical Cellular Pathology. 2019. 1–9. 8 indexed citations

Lu, Huiqi, Guanghui Wang, Zhewei Wang, et al.. (2019). A Hallmark-Based Six-Gene Expression Signature to Assess Colorectal Cancer and Its Recurrence Risk. Genetic Testing and Molecular Biomarkers. 23(8). 557–564. 1 indexed citations

Wu, Tingyu, Guanghui Wang, Wei Chen, et al.. (2018). Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Cell Death and Disease. 9(3). 315–315. 35 indexed citations

10.

Wu, Tingyu, Wei Chen, Yongwang Zhong, et al.. (2016). Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor. Molecular Cancer Therapeutics. 16(4). 717–728. 17 indexed citations

11.

Kitagaki, Jirouta & Yili Yang. (2011). DNA intercalator korkormicin A preferentially kills tumor cells expressing wild type p53. Biochemical and Biophysical Research Communications. 414(1). 186–191. 5 indexed citations

12.

Yin, Jie, Xuedong Yan, Xin Yao, et al.. (2011). Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. Journal of Cellular and Molecular Medicine. 16(2). 337–348. 106 indexed citations

13.

Hodge, Deborah L., Jun Yang, Matthew D. Buschman, et al.. (2009). Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias. Cancer Research. 69(9). 3986–3994. 50 indexed citations

14.

Weissman, Allan M., et al.. (2008). Inhibiting Hdm2 and Ubiquitin-Activating Enzyme: Targeting the Ubiquitin Conjugating System in Cancer. PubMed. 171–190. 11 indexed citations

15.

Yang, Yili, Jirouta Kitagaki, Honghe Wang, De‐Xing Hou, & Alan O. Perantoni. (2008). Targeting the ubiquitin‐proteasome system for cancer therapy. Cancer Science. 100(1). 24–28. 109 indexed citations

16.

Yang, Yili, Jirouta Kitagaki, Ren‐Ming Dai, et al.. (2007). Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics. Cancer Research. 67(19). 9472–9481. 372 indexed citations

17.

Yang, Yili, Robert L. Ludwig, Jane P. Jensen, et al.. (2005). Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 7(6). 547–559. 263 indexed citations

18.

Yang, Yili & Jonathan D. Ashwell. (2001). Exploiting the apoptotic process for management of HIV: Are we there yet?. APOPTOSIS. 6(1-2). 139–146. 10 indexed citations

19.

Kadereit, Suzanne, Hui Xu, Tara M. Engeman, et al.. (2000). Negative Regulation of CD8+ T Cell Function by the IFN-Induced and Double-Stranded RNA-Activated Kinase PKR. The Journal of Immunology. 165(12). 6896–6901. 25 indexed citations

20.

Yang, Yili, Mladen Merćep, Carl F. Ware, & Jonathan D. Ashwell. (1995). Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids.. The Journal of Experimental Medicine. 181(5). 1673–1682. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact